March 27, 2023
Iovance Biotherapeutics submits BLA to FDA for advanced melanoma drug lifileucel
Iovance Biotherapeutics has completed submission of the Biologics License Application (BLA) for lifileucel to the US Food and Drug Administration (FDA).